Two centuries. Countless innovations. One vision.
Takeda Breaks Ground on its First Zero Energy Building in Singapore
Takeda Selects Four New Partners for Annual Global Corporate Social Responsibility (CSR) Program to Help Strengthen Health Systems in Low- and Middle-Income Countries
Takeda Continues to Advance Growth Strategy with Sale Of Non-Core Assets in Latin America
Takeda’s EXKIVITY™ (mobocertinib) Approved by U.S. FDA as the First Oral Therapy Specifically Designed for Patients with EGFR Exon20 Insertion+ NSCLC
Takeda to Manufacture and Provide 150 Million Doses of Novavax’ COVID-19 Vaccine Candidate to the Government of Japan
SEE ALL NEWS AND RELEASES >
・For Shire news releases, click here
Luck is not a strategy: The world needs to start preparing now for the next pandemic
The COVID-19 Mental Burden on Working Mothers
Takeda Neuroscience at the Annual Meeting of the American Academy of Neurology (AAN) 2021
Takeda Breaks Ground on Commercial Cell Therapy Manufacturing Facility in Lexington, Massachusetts
Spotlight Malawi: Many Paths Towards Universal Health Coverage and a Strong Health Workforce
SEE ALL FEATURED TOPICS ARTICLES >
With this new original series featured in Asahi Shimbun Globe, President & CEO Christophe Weber gives his unique perspective on what he has learned from his upbringing in France and his international career.
For media inquiries or reporter requests for more information, contact our Corporate Communications via Media_Relations@takeda.com. If you generally would like to contact us, please visit Contact Us.
Copyright 1995-2021 Takeda Pharmaceutical Company Limited. All rights reserved.